Author:
Hey-Hadavi Juliana,Seekins Daniel,Palmer Melissa,Coffey Denise,Caminis John,Abdullaev Sandzhar,Patwardhan Meenal,Tyler Haifa,Raheja Ritu,Stanley Ann Marie,Pineda-Salgado Liliam,Bourdet David L.,Andrade Raul J.,Hayashi Paul H.,Dimick-Santos Lara,Rockey Don C.,Estilo Alvin
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference70 articles.
1. Regev A, Seeff LB, Merz M, Ormarsdottir S, Aithal GP, Gallivan J, et al. Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf. 2014;37:47–56.
2. Watkins PB. How to diagnose and exclude drug-induced liver injury. Dig Dis. 2015;33:472–6.
3. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117–26.
4. Hayashi PH. Drug-induced liver injury network causality assessment: criteria and experience in the United States. Int J Mol Sci. 2016;17:201.
5. U.S. Food and Drug Administration (FDA). Guidance for industry drug-induced liver injury: premarketing clinical evaluation. https://www.fda.gov/downloads/guidances/UCM174090.pdf. Accessed 29 Aug 2017.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献